博雅生物(300294.SZ):擬變更公司名稱為“華潤博雅生物製藥集團股份有限公司”
格隆匯1月12日丨博雅生物(300294.SZ)公佈,經公司第七屆董事會第十三次會議審議,通過了《關於變更公司名稱的議案》,鑑於華潤醫藥控股有限公司(以下簡稱“華潤醫藥控股”)成為公司控股股東,中國華潤有限公司成為公司實際控制人。
經華潤(集團)有限公司(以下簡稱“華潤集團”)出具的《關於授權使用“華潤”字號的函》授權,公司擬將中文名稱“博雅生物製藥集團股份有限公司”變更為“華潤博雅生物製藥集團股份有限公司”(最終變更名稱以工商管理部門核准為準)。同時,公司英文名稱由“BoyaBio-pharmaceutical Group Co.,Ltd”變更為“China Resources BoyaBio-pharmaceutical Group Co.,Ltd”。根據華潤集團的授權文件,華潤集團同意公司在企業名稱中使用“華潤”字號,且使用期限與公司經營期限相同(至長期)。但在此期限內,如公司不再被華潤集團視為下屬企業,此授權自動失效,授權期限自動終止。
公司名稱變更後,公司證券簡稱及證券代碼保持不變,證券簡稱仍然為“博雅生物”,證券代碼仍然為“300294”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.